Phase 1Recruiting
Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia
A Randomized Crossover Open-Label Trial of Naproxen and Metformin Safety and Tolerability in the Setting of Prevention of Oral Cancer in Fanconi Anemia
- Sponsor
- Rockefeller University (Academic or other)
- Enrollment
- 80 planned
- Conditions
- Fanconi Anemia; Head and Neck Cancer; Squamous Cell Carcinoma; Squamous Cell Cancer of Head and Neck (SCCHN)
- Interventions
- Metformin; Naproxen Sodium
- Ages
- adults, older adults
- Registry
- NCT07901959
Full record on ClinicalTrials.gov
From the registry
Finding effective ways to slow down or prevent the development of cancer in people with Fanconi anemia (FA) is a critical medical priority. Individuals with FA are at dramatically higher risk of developing aggressive cancers, particularly of the head and neck, and these cancers are difficult to treat with standard therapies such as surgery, chemotherapy or radiation. Because options for treatment are limited and outcomes are often poor, prevention strategies are urgently needed. In this study, the investigators will test two widely available drugs, metformin and naproxen, to evaluate whether they can lower the risk of cancer in FA patients. Metformin is commonly prescribed for type 2 diabetes, while naproxen is a nonsteroidal anti-inflammatory drug (NSAID) frequently used for pain and inflammation. Both have shown potential in previous research to influence biological pathways linked to cancer development. By repurposing these well-known drugs, this trial aims to explore a safe, practical approach to cancer prevention in this vulnerable population. The study, conducted at the…
Primary outcomes
- Safety
- Tolerability of Intervention Regimen
History
Study completion expected
Primary completion expected
Registered
Started